Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
CT-322 · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| CT-322 | DRUG | IV solution, weekly or bi-weekly |
DISEASE CHARACTERISTICS * Histologically proven advanced solid malignancy or NHL for which no standard therapy exists or for which standard therapy had failed * No known brain or leptomeningeal disease * No prior bone marrow transplant or stem cell rescue * No histologically confirmed squamous non-...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/ GEH200521- Part A |
| Zimmer Biomet Holdings, Inc. | ZBH | 1 | - | Undisclosed |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
CT-322 is an investigational small molecule being studied for the treatment of cancer. It was evaluated in a Phase 1 clinical trial in patients with advanced solid tumors and non-Hodgkin's lymphoma. The drug is in early clinical development and is not approved for any use.
CT-322 is being developed by Bristol-Myers Squibb Company, which trades under the ticker symbol BMY. The company is conducting clinical research on this investigational oncology drug.
CT-322 is in Phase 1 clinical development. A Phase 1 trial has been completed, and the drug remains investigational. It has not been approved by regulatory authorities, and its safety and efficacy are still being evaluated.
CT-322 has been studied in one completed Phase 1 clinical trial with the identifier NCT00374179. The trial enrolled 40 participants with advanced solid tumors and non-Hodgkin's lymphoma in the United States. It was an uncontrolled, open-label study.
CT-322 is not FDA approved. It is an investigational drug that has completed a Phase 1 clinical trial. Further studies would be needed to establish its safety and effectiveness before any regulatory approval could be considered.